Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/173228
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHurtado Guerrero, Isaac-
dc.contributor.authorHernáez, Bruno-
dc.contributor.authorPinto Medel, María J.-
dc.contributor.authorCalonge, Esther-
dc.contributor.authorRodríguez Bada, José L.-
dc.contributor.authorUrbaneja, Patricia-
dc.contributor.authorAlonso, Ana-
dc.contributor.authorMena Vázquez, Natalia-
dc.contributor.authorAliaga, Pablo-
dc.contributor.authorIssazadeh Navikas, Shohreh-
dc.contributor.authorPavia, José-
dc.contributor.authorLeyva, Laura-
dc.contributor.authorAlcamí, Antonio-
dc.contributor.authorAlcamí, José-
dc.contributor.authorFernández, Óscar-
dc.contributor.authorOliver Martos, Begoña-
dc.date.accessioned2021-01-19T18:15:34Z-
dc.date.available2021-01-19T18:15:34Z-
dc.date.issued2020-04-01-
dc.identifier.urihttps://hdl.handle.net/2445/173228-
dc.description.abstractSoluble receptors of cytokines are able to modify cytokine activities and therefore the immune system, and some have intrinsic biological activities without mediation from their cytokines. The soluble interferon beta (IFN-ss) receptor is generated through alternative splicing of IFNAR2 and has both agonist and antagonist properties for IFN-ss, but its role is unknown. We previously demonstrated that a recombinant human soluble IFN-ss receptor showed intrinsic therapeutic efficacy in a mouse model of multiple sclerosis. Here we evaluate the potential biological activities of recombinant sIFNAR2 without the mediation of IFN-ss in human cells. Recombinant sIFNAR2 down-regulated the production of IL-17 and IFN-? and reduced the cell proliferation rate. Moreover, it showed a strong antiviral activity, fully protecting the cell monolayer after being infected by the virus. Specific inhibitors completely abrogated the antiviral activity of IFN-ss, but not that of the recombinant sIFNAR2, and there was no activation of the JAK-STAT signaling pathway. Consequently, r-sIFNAR2 exerts immunomodulatory, antiproliferative and antiviral activities without IFN-ss mediation, and could be a promising treatment against viral infections and immune-mediated diseases.-
dc.format.extent20 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm9040959-
dc.relation.ispartofJournal of Clinical Medicine, 2020, vol. 9, num. 4-
dc.relation.urihttps://doi.org/10.3390/jcm9040959-
dc.rightscc by (c) Hurtado Guerrero et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationImmunologia-
dc.subject.classificationInterferó-
dc.subject.otherImmunology-
dc.subject.otherInterferon-
dc.titleAntiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-beta Mediation-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2020-12-21T13:11:24Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid32244308-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Hurtado-GuerreroI.pdf4.08 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons